The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection (CurHP)
Primary Purpose
Positivity for Helicobacter Pylori
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Curcumin
Sponsored by

About this trial
This is an interventional treatment trial for Positivity for Helicobacter Pylori
Eligibility Criteria
Inclusion Criteria:
- positivity for Helicobacter pylori by urease test and gastric biopsy
Exclusion Criteria:
- prior treatment for H. pylori
- allergy to penicillin
- gastric outlet obstruction
- pregnancy or breast feeding
- inability to understand the informed consent
Sites / Locations
- Rabin Medical Center
- Rabin Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Triple therapy, helicobacter pylori
triple therapy+curcumin helicobacter pylori
Arm Description
Curcumin will be added to the regular triple therapy
Outcomes
Primary Outcome Measures
Urea breath test
Secondary Outcome Measures
Full Information
NCT ID
NCT02018328
First Posted
December 17, 2013
Last Updated
December 13, 2014
Sponsor
Gingold Belfer Rachel
1. Study Identification
Unique Protocol Identification Number
NCT02018328
Brief Title
The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection
Acronym
CurHP
Official Title
The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Unknown status
Study Start Date
January 2014 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Gingold Belfer Rachel
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background and Aims
H.pylori is a common human pathogen by which almost 50% of the world population is infected. According to the accepted guidelines, once H.pylori infection has been diagnosed,first line therapy with three drugs should be given. The triple treatment includes proton-pump-inhibitor-clarithromycin-amoxicillin but its eradication rate is only 70-80%.
Curcumin has many beneficial merits and it was also been demonstrated to be efficient in inhibition of H.pylori infection, in vitro.Therefore we aim to investigate whether addition of Curcumin to the standard triple therapy will increase the eradication rate of H.pylori infection.
Methods
150 consecutive patients that will undergo esophagogastroscopy in our Gastroenterology department and will be positive for H.pylori according to urease test and then by gastric biopsy, will be included. The patients will be randomized to two different treatments, according to binomial distribution. 75 patients will be treated with the standard triple therapy for 10 days and the other 75, will be treated for 10 days, with triple therapy combined with Curcumin that will be given three times a day.
During the treatment the patients will complete an adverse effect's questionnaires. 6 weeks after the completion of the treatment the patients will undergo urea breath test to confirm eradication. Patients will be asked to avoid antibiotics, bismuth compounds or proton-pump-inhibitor until the second urea-breath-test.
We will compare the eradication rate and the adverse effects between the two groups by using SPSS
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Positivity for Helicobacter Pylori
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Triple therapy, helicobacter pylori
Arm Type
No Intervention
Arm Title
triple therapy+curcumin helicobacter pylori
Arm Type
Experimental
Arm Description
Curcumin will be added to the regular triple therapy
Intervention Type
Dietary Supplement
Intervention Name(s)
Curcumin
Primary Outcome Measure Information:
Title
Urea breath test
Time Frame
6 weeks after the completion of the treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
positivity for Helicobacter pylori by urease test and gastric biopsy
Exclusion Criteria:
prior treatment for H. pylori
allergy to penicillin
gastric outlet obstruction
pregnancy or breast feeding
inability to understand the informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rachel Gingold belfer, MD
Email
RahelGB@clalit.org.il
Facility Information:
Facility Name
Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel Gingold Belfer, MD
Phone
974-54-2405895
Email
RahelGB@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Rachel Gingold Belfer, MD
Facility Name
Rabin Medical Center
City
Petah tikva
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel Gingold Belfer, MD
Phone
974-54-2405895
Email
RahelGB@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Rachel Ginold Belfer, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
15044093
Citation
Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Commun. 2004 Apr 16;316(4):1065-72. doi: 10.1016/j.bbrc.2004.02.158.
Results Reference
background
Learn more about this trial
The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection
We'll reach out to this number within 24 hrs